Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Darunavir Stories

2014-04-07 08:30:46

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 7, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Pfizer Inc. (NYSE: PFE), Merck & Co., Inc. (NYSE: MRK), GlaxoSmithKline plc (NYSE: GSK), and Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings...

2014-04-01 08:28:25

RARITAN, N.J., April 1, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen), today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a once-daily fixed-dose antiretroviral combination tablet containing darunavir, a protease inhibitor developed by Janssen R&D Ireland and marketed as PREZISTA(®) in the U.S., with cobicistat, an investigational pharmacokinetic enhancer or boosting agent, developed...

2014-03-06 08:30:17

Additional drug-drug interaction data for faldaprevir combined with commonly prescribed HIV medications also presented at CROI 2014 INGELHEIM, Germany and RIDGEFIELD, Conn., March 6, 2014 /PRNewswire/ -- Today Boehringer Ingelheim announced results from STARTVerso(®)4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg...

2013-12-09 04:21:28

Sub-Saharan African Ministries of Health Invited to Submit Expression of Interest to Participate in New Effort CAPE TOWN, South Africa, Dec. 9, 2013 /PRNewswire/ -- Janssen, the pharmaceutical companies of Johnson & Johnson, today announced a first-of-its-kind pediatric HIV treatment donation program to improve access to the company's approved HIV medicines for children and adolescents failing HIV treatment in sub-Saharan Africa. At a symposium entitled When Children Need HIV...

2013-11-22 20:22:56

OLYSIO(TM) is the first once-daily protease inhibitor approved for the treatment of chronic hepatitis C in a combination antiviral regimen for adults with compensated liver disease TITUSVILLE, N.J., Nov. 22, 2013 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), announced today the U.S. Food and Drug Administration (FDA) has approved OLYSIO((TM)) (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an...

2013-10-15 04:21:04

BEERSE, Belgium, October 15, 2013 /PRNewswire/ -- Janssen-Cilag International NV (Janssen), today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency seeking approval for a once-daily single tablet fixed-dose antiretroviral combination product containing darunavir, a protease inhibitor developed by Janssen, with cobicistat, a pharmacokinetic enhancer or boosting agent, developed by Gilead Sciences, Inc. (Gilead) for use in...

2013-09-12 20:21:33

DENVER, Sept. 12, 2013 /PRNewswire/ -- ViiV Healthcare today announced initial results from the Phase IIIb/IV FLAMINGO (ING114915) study. This open-label study, for the first time, compared once-daily regimens containing 50mg dolutegravir with once-daily regimens containing a protease inhibitor (PI) (800mg darunavir boosted with 100mg ritonavir) in treatment-naive adults with HIV-1. Both treatment arms were administered with investigator-selected dual NRTIs. Non-inferiority was demonstrated...

2013-05-30 12:27:02

Most Survey Participants Would Recommend Joining a Study to Others TITUSVILLE, N.J., May 30, 2013 /PRNewswire/ -- A survey of a segment of clinical trial participants from the GRACE (Gender, Race And Clinical Experience) trial, the largest-ever study of treatment-experienced adult women with HIV to examine gender differences in response to HIV therapy, found that after taking part in the study, 96 percent of survey responders would recommend participation in a clinical trial to...

2013-05-06 08:30:54

- Interferon-free, direct-acting antiviral combination therapy currently in Phase 3 development NORTH CHICAGO, Ill., May 6, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its investigational direct-acting antiviral (DAA) combination with and without ribavirin for the treatment of genotype 1 (GT1) hepatitis C virus (HCV) infection has been designated as a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA). The designation is based, in part, on...

2013-04-30 08:34:46

-- TMC310911 is Third Product in Growing Ascletis Pipeline of Infectious Disease and Cancer Therapeutics -- HANGZHOU, China and RESEARCH TRIANGLE PARK, N.C., April 30, 2013 /PRNewswire/ -- Ascletis today announced that the company has licensed development, manufacturing and commercialization rights from Janssen R&D Ireland to TMC310911, a next-generation HIV protease inhibitor (PI). The agreement provides Ascletis with exclusive rights to develop and commercialize TMC310911 in...